Announcements Trials
Browse Landscape

Phase

Phase 1/2 5Phase 1 5Phase 2 1

Status

Completed 5

Sponsor Class

NIH 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Sarcoma 5CNS 5

Conditions

Glioblastoma 6Gliosarcoma 5Brain Neoplasms 5Prostatic Neoplasms 4Oligodendroglioma 3Lymphoma, Non-Hodgkin 3Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Glioma 3Astrocytoma 3Waldenstrom Macroglobulinemia 2Lymphoma, B-Cell, Marginal Zone 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Synovial 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Pancreatic Neoplasms 1Osteosarcoma 1Neurofibrosarcoma 1Neoplasms, Squamous Cell 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma, T-Cell 1

Interventions

Temozolomide 26Bevacizumab 14Radiosurgery 12Radiotherapy 9pembrolizumab 8Carboplatin 8Trastuzumab 6temsirolimus 5Sirolimus 5Erlotinib Hydrochloride 5abemaciclib 4Paclitaxel 4Irinotecan 4Capecitabine 4tipifarnib 3Sorafenib 3Radiation 3Mental Status and Dementia Tests 3Ipilimumab 3Everolimus 3Aminolevulinic Acid 3130-nm albumin-bound paclitaxel 3tucatinib 2pertuzumab 2fludarabine 2durvalumab 2alovudine 2alectinib 2Vorinostat 2Surgical Procedures, Operative 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1/2 × Brain Neoplasms × temsirolimus × Clear all
NCT01051557 2021-07-19

Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma

National Cancer Institute (NCI)

Phase 1/2 Completed
36 enrolled 15 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

NCT00329719 2018-10-16

Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma

National Cancer Institute (NCI)

Phase 1/2 Completed
115 enrolled 13 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT00335764 2018-07-02

Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma

National Cancer Institute (NCI)

Phase 1/2 Completed
92 enrolled 24 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT00022724 2018-06-26

CCI-779 in Treating Patients With Malignant Glioma

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1/2 Completed
49 enrolled
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

NCT00112736 2015-06-15

Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma

National Cancer Institute (NCI)

Phase 1/2 Completed
69 enrolled 12 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡